Search - tctmd.com

Displaying 721 - 740 of 764

Sort: Relevancy | Date

News Daily News

Meta-analysis: Everolimus-Eluting Stents Reduce Thrombosis vs. Other DES

September 14, 2011

News Daily News

Long-term Outcomes Similar for Biodegradable-Polymer, Permanent-Polymer DES

September 12, 2011

News Conference News

ESC Congress 2011: Drugs, Devices Work Together

Caitlin E. Cox

September 06, 2011

News Conference News

Two Trials Show Favorable Results with XIENCE V vs. Earlier DES, BMS

September 02, 2011

News Conference News

RESET: Largest Study to Date of Xience, Cypher Shows Noninferiority

August 31, 2011

News Conference News

Long-term Antiplatelet Therapy: All Risk, No Benefit

August 30, 2011

News Conference News

New-Generation DES Reduce Restenosis, Stent Thrombosis

August 29, 2011

News Daily News

TRIAS HR Published: Genous Stent Doubles Target Lesion Failure

Leah Lawrence

August 23, 2011

News Daily News

No Apparent Advantage for Everolimus vs. Paclitaxel Stents in Diabetic Patients

L.A. McKeown

August 19, 2011

News Daily News

ESSENCE-DIABETES Published: Xience, Cypher Equally Equipped to Treat Diabetics

Caitlin E. Cox

August 03, 2011

News Daily News

Meta-analysis Finds Equivalence Between First-, Second-Generation DES

L.A. McKeown

August 02, 2011

News Daily News

Cordis Announces Plans to Discontinue Cypher Stents, Drop Nevo Development

L.A. McKeown

June 15, 2011

News Daily News

RESOLUTE All Comers Looks at Simple, Complex Cases in Comparing ZES, EES

L.A. McKeown

June 10, 2011

News Industry News

Boston Scientific Announces Favorable Appellate Court Ruling Affirming Invalidity of J & J Patents

June 07, 2011

News Industry News

Boston Scientific Announces FDA Approval and U.S. Launch of PROMUS® 2.25 mm Everolimus-Eluting Coronary Stent System

May 25, 2011

News Daily News

EES Show Long-term Safety Advantage over SES

L.A. McKeown

May 24, 2011

News Industry News

Abbott Receives U.S. FDA Approval for XIENCE nano™ to Treat Coronary Artery Disease in Small Vessels

May 24, 2011

News Industry News

PROMUS Element™ Stent Demonstrates Exceptional Safety and Effectiveness in PLATINUM Small Vessel Study

May 20, 2011

News Industry News

Titanium-Nitride-Oxide Bio Active Technology in ACS Patients: Present and Future

May 18, 2011

News Daily News

Robot-Assisted PCI Shows Promise in Early Clinical Experience

Caitlin E. Cox

April 29, 2011

Advertisement

Meta-analysis: Everolimus-Eluting Stents Reduce Thrombosis vs. Other DES

Long-term Outcomes Similar for Biodegradable-Polymer, Permanent-Polymer DES

ESC Congress 2011: Drugs, Devices Work Together

Two Trials Show Favorable Results with XIENCE V vs. Earlier DES, BMS

RESET: Largest Study to Date of Xience, Cypher Shows Noninferiority

Long-term Antiplatelet Therapy: All Risk, No Benefit

New-Generation DES Reduce Restenosis, Stent Thrombosis

TRIAS HR Published: Genous Stent Doubles Target Lesion Failure

No Apparent Advantage for Everolimus vs. Paclitaxel Stents in Diabetic Patients

ESSENCE-DIABETES Published: Xience, Cypher Equally Equipped to Treat Diabetics

Meta-analysis Finds Equivalence Between First-, Second-Generation DES

Cordis Announces Plans to Discontinue Cypher Stents, Drop Nevo Development

RESOLUTE All Comers Looks at Simple, Complex Cases in Comparing ZES, EES

Boston Scientific Announces Favorable Appellate Court Ruling Affirming Invalidity of J & J Patents

Boston Scientific Announces FDA Approval and U.S. Launch of PROMUS® 2.25 mm Everolimus-Eluting Coronary Stent System

EES Show Long-term Safety Advantage over SES

Abbott Receives U.S. FDA Approval for XIENCE nano™ to Treat Coronary Artery Disease in Small Vessels

PROMUS Element™ Stent Demonstrates Exceptional Safety and Effectiveness in PLATINUM Small Vessel Study

Titanium-Nitride-Oxide Bio Active Technology in ACS Patients: Present and Future

Robot-Assisted PCI Shows Promise in Early Clinical Experience

Advertisement

Advertisement

Sign In

Forgot Your Password?

Search TCTMD

CME TITLE

Sign up for our newsletter

Search TCTMD

Submit an Event

Become a PREMIUM MEMBER or LOG IN to view exclusive content

REGISTER for free or LOG IN to view this content